Evidence map›Paper›PMID 26578613›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes.

Lawrence N Shulman, Claire M Wagner, Ronald Barr, Gilberto Lopes, Giuseppe Longo, Jane Robertson, Gilles Forte, Julie Torode, Nicola Magrini

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Screening for distress among metastatic breast cancer patients at a tertiary cancer center in Southwest Nigeria: Using the NCCN distress thermometer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Uptake of orphan drugs in the WHO essential medicines lists.Bulletin of the World Health Organization · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. An urgent call to raise the bar in oncology.British journal of cancer · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lawrence N ShulmanLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy. lawrence.shulman@uphs.upenn.edu.
Claire M WagnerLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Ronald BarrLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Gilberto LopesLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Giuseppe LongoLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Jane RobertsonLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Gilles ForteLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Julie TorodeLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
Nicola MagriniLawrence N. Shulman and Claire M. Wagner, Dana-Farber Cancer Institute; Lawrence N. Shulman, Partners In Health, Boston, MA; Claire M. Wagner and Julie Torode, Union for International Cancer Control; Jane Robertson, Gilles Forte, and Nicola Magrini, World Health Organization, Geneva, Switzerland; Ronald Barr, McMaster University, Hamilton, Ontario, Canada; Gilberto Lopes, Centro Paulista de Oncologia e Hcor Onco, São Paulo, Brazil; Gilberto Lopes, Johns Hopkins University, Baltimore, MD; and Giuseppe Longo, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.

Funding

World Health Organization 001
6 · The paper itself

Abstract

purposeA great proportion of the world's cancer burden resides in low- and middle-income countries where cancer care infrastructure is often weak or absent. Although treatment of cancer is multidisciplinary, involving surgery, radiation, systemic therapies, pathology, radiology, and other specialties, selection of medicines that have impact and are affordable has been particularly challenging in resource-constrained settings. In 2014, at the invitation of the WHO, the Union for International Cancer Control convened experts to develop an approach to propose essential cancer medicines to be included in the WHO Model Essential Medicines Lists (EML) for Adults and for Children, as well as a resulting new list of cancer medicines.

methodsExperts identified 29 cancer types with potential for maximal treatment impact, on the basis of incidence and benefit of systemic therapies. More than 90 oncology experts from all continents drafted and reviewed disease-based documents outlining epidemiology, diagnostic needs, treatment options, and benefits and toxicities.

resultsBriefing documents were created for each disease, along with associated standard treatment regimens, resulting in a list of 52 cancer medicines. A comprehensive application was submitted as a revision to the existing cancer medicines on the WHO Model Lists. In May 2015, the WHO announced the addition of 16 medicines to the Adult EML and nine medicines to the Children's EML.

conclusionThe list of medications proposed, and the ability to link each recommended medicine to specific diseases, should allow public officials to apply resources most effectively in developing and supporting nascent or growing cancer treatment programs.

Indexed as

Drugs, EssentialHumansNeoplasmsTreatment OutcomeDrugs, Essential

Identifiers

PMID26578613
PMCPMC5070565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.